PDE12

Across TCGA pan-cancer cohorts, PDE12 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDE12 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDE12 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PDE12 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where PDE12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.853	0.435	<.001	28	view →
GBM	DFS	Quartile	All	0.202	0.437	.019	5	view →
CCRCC	OS	Tertile	All	0.934	0.776	.016	3	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDE12–PDAC (OS)

Open the PDAC breakdown →